trial · primary record
Cabozantinib
Non-Small Cell Lung Cancer
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 86 |
| Primary completion | 2027-07 |
| Primary endpoint | objective response rate (ORR) (Group A) |
| Registry ID | NCT01639508 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:41:35.648Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT01639508
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Cabozantinib · approval
- Cabozantinib · compound